Expression of MAGE, GAGE and BAGE genes in human liver diseases: Utility as molecular markers for hepatocellular carcinoma

Journal of Hepatology

Volumn 32, Issue 4, 2000, Pages 612-617

  Kobayashi, Yoshiyuki ^a   Higashi, Toshihiro ^a,b   Nouso, Kazuhiro ^a   Nakatsukasa, Harushige ^a   Ishizaki, Masahiko ^a   Kaneyoshi, Toshihiko ^a   Toshikuni, Nobuyuki ^a   Kariyama, Kazuya ^a   Nakayama, Eiichi ^c   Tsuji, Takao ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NONE

Author keywords

BAGE; Diagnosis; GAGE; Hepatocellular carcinoma; Immunotherapy; MAGE

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CELL DIFFERENTIATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL;

EID: 0034076068     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80223-8     Document Type: Article

References (41)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, et al. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J Exp Med. 178:1993;489-495.
3. Kawakami Y, Eliyahu S, Delgado CH, Robbins P, Riroltini L, Toplalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 91:1994;3515-3519.
4. van der Bruggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw 1601. Eur J Immunol. 24:1994;2134-2140.
5. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio SS, De Plaen E, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:1994;921-930.
6. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 24:1994;3038-3043.
7. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leucocytes antigen-A24. Cancer Res. 57:1997;4465-4468.
8. Boel P, Wildmann C, Luisa Sensi M, Braseur R, Renauld JC, Coulie P, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:1995;167-175.
9. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 182:1995;689-698.
10. De Smet C, Lurquin C, van der Bruggen P, De Plaen E, Brasseur F, Boon T. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics. 39:1994;121-129.
11. Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother. 39:1994;105-116.
12. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 92:1995;11810-11813.
13. Hoon DSB, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol. 154:1995;730-737.
14. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 63:1995;883-885.
15. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer. 67:1996;54-62.
16. Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, et al. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer. 72:1997;972-976.
17. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptides- or tumor lysate-pulsed dendritic cells. Nat Med. 4:1998;328-332.
18. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, et al. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology. 24:1996;1437-1440.
19. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 15:1992;948-963.
20. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B-and C-viral infection in Japan. Hepatology. 22:1995;1027-1033.
21. Ohto M, Sugimura N, Ebara M. Treatment of hepatocellular carcinoma by alcohol injection into tumor and irradiation of tumor. Jpn J Cancer Chemother. 18:1986;1625-1634.
22. Farmer DG, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for hepatocellular carcinoma. Ann Surg. 219:1994;236-247.
23. Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, et al. Prognostic factors after hepatectomy for hepatocellular carcinoma. Cancer. 65:1990;1104-1110.
24. Imaoka S, Sasaki Y, Ishikawa O, Ouhigashi H, Iwanaga T, Ishiguro S. Immunochemotherapy in human hepatocellular carcinoma using the streptococcal agent OK-432. J Clin Oncol. 4:1986;1645-1651.
25. Komatsu T, Yamauchi K, Furukawa T, Obata H. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells intopatients with liver cancers. J Clin Immunol. 10:1990;167-174.
26. Oka M, Hazama S, Yoshino S, Shimoda K, Suzuki M, Shimizu R, et al. Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results. Cancer Immunol Immunother. 38:1994;194-200.
27. Foley WD, Hoffmann RG, Quiroz FA, Kahn CE, Perret RS. Hepatic helical CT:contrast material injection protocol. Radiology. 192:1994;367-371.
28. Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, et al. Imaging diagnosis of small hepatocellular carcinoma. Hepatology. 20:1994;82-87.
29. Eguchi A, Nakashima O, Okudaira S, Sugihara S, Kojiro M. Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology. 15:1992;843-848.
30. Taketa K. α-fetoprotein: reevaluation in hepatology. Hepatology. 12:1990;1420-1432.
31. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-γ-carboxy (abnormal) prothrombin as a marker of primary hepatocellular carcinoma. N Engl J Med. 310:1984;1427-1431.
32. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 22:1995;983-993.
33. Kariyama K, Higashi T, Kobayashi Y, Nouso K, Nakatsukasa H, Yamano T, et al. Expression of MAGE-1 and -3 gene products in human hepatocellular carcinoma. Br J Cancer (in press).
34. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, et al. The expression of tumor-rejection antigen"MAGE" genes in human gastric carcinoma. Gastoenterology. 109:1995;1522-1525.
35. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer. 56:1994;826-829.
36. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-Aza-2′deoxycytidine. Cancer Res. 54:1994;1766-1771.
37. Hoon DSB, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 13:1995;2109-2116.
38. Cheung IY, Cheung NV. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res. 3:1997;821-826.
39. Dong RP, Kimura A, Okubo R, Shinagawa H, Tamai H, Nishimura Y, et al. HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol. 35:1992;165-172.
40. Celis E, Fikes J, Wentworth P, Sidney J, Southwood S, Maewal A, et al. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol. 31:1994;1423-1430.
41. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. Tsuji K, Aizawa M, Sasazuki T. HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference. 1992;1065-1068 Oxford University Press, Oxford.